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ABSTRACT 
For the first time in vitro experiments there were studied the inhibitory activity and safety of 
potential molecules arginase II selective inhibitors from the group of norleucine derivatives. Also 
first the substance under the code ZB49-0010C from the group of norleucine derivatives showed the 
greatest selectivity and inhibitory activity against arginase II in experiments in vitro. However, this 
substance in vivo exerts dose-dependent hypotensive action and cardioprotective and endothelial 
protective effects on the L-NAME induced and homocysteine-induced endothelial dysfunction (ED), 
which are most pronounced at a dose of 10 mg/kg in intragastric administration. Endothelial 
protective effect consists of in preventing the increase of coefficient of endothelial dysfunction 
(CED) and the decrease in the concentration of stable metabolites of nitric oxide in the blood 
plasma. Cardioprotective effect consists of in preventing the increase of the level of left ventricular 
pressure during the test for adrenoreactivity and reducing of the cardiac reserve during the overload 
resistance test, and also in preventing the development of the left ventricular hypertrophy. As part of 
the study there was investigated the dose-dependent anti-ischemic effect of the arginase II selective 
inhibitor, substance ZB49-0010C on the chronic limb ischemia in rats, which most pronounced at a 
dose of 10 mg/kg and consists of in preventing the fall in microcirculatory level on the 29th day of 
the experiment in the ischemic limb and a protective effect based on the morphological examination 
of the muscle tissue. 
Key words: arginase II selective inhibitors, ZB49-0010C, L-NAME, endothelial dysfunction, nitric 
oxide, methionine, homocysteine, ischemia, cardioprotective effect. 
To date, the morbidity and, most importantly, 
the disablement and mortality from cardiovascular 
diseases have no tendency to decrease, despite the 
presence of a huge number of tools and methods like 
medication and non-drug therapy, which in itself 
reflects the limited therapeutic possibilities of 
modern medicine, or about the faulty and deadlock 
the paradigm of pharmacotherapy of cardiovascular 
diseases. As long as modern medicine will not find 
adequate and effective treatment modalities of 
cardiovascular diseases, the search for new 
therapeutic targets and molecules will not lose its 
relevance and priority for innovation 
cardiopharmacology. 
According to the most progressive of existing 
paradigms, a key element in the pathogenesis of the 
majority of such cardiovascular diseases as 
atherosclerosis, arterial hypertension, atherosclerotic 
cardiovascular disease (CAD), acute cerebrovascular 
event, dyscirculatory encephalopathy (DEP), chronic 
arterial insufficiency of the lower extremities is an 
ED [1, 2, 3, 4]. ED is the imbalance between humoral 
factors having vasodilatatory and antiplatelet action 
(NO, endothelium-derived hyperpolarizing factor, 
prostaglandins), and vasospastic and haemostatic 
system activation factors (endothelin-1, thromboxane 
A2, superoxide anion). Thus, a key element of the 
pathogenesis of ED is the deficit of endogenous NO. 
Normally functioning endothelium continuously 
produces NO via endothelial NO synthase (eNOS) 
from L-arginine [5, 6, 7, 8, 9].  
However, along with deficit of NO production, a 
decrease in its bioaccessibility has a significant 
importance in the pathogenesis of ED, which may be 
due to increase level in plasma asymmetric 
dimethylarginine (ADMA), an endogenous 
competitive еNOS inhibitor. Another mechanism of 
NO reduction is associated with increased production 
of oxygen free radicals [4, 9, 10].  
As you know, L-arginine as the only substrate 
for NO synthesis, is actively biotransformed under 
the influence of arginase. The concentration of L-
arginine in the blood plasma varies depending on a 
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great many corrected and non-corrected factors [5, 6, 
7, 8, 11,12, 13].  
It is known that the metabolism of L-arginine in 
the cells occurs in two ways (the first way L-arginine 
is hydrolyzed by arginase to ornithine and urea. The 
second L-arginine is metabolized to nitric oxide and 
citrulline that is catalyzed by NO synthase. Enzymes 
arginase and NO-synthase compete for the common 
substrate  L-arginine [4, 9, 14, 15]. 
Arginase has a high activity exceeding the 
activity of NO-synthase. It is represented as two 
isoforms: arginase I is liver and arginase II is the 
extrahepatic form, localized more frequently in the 
kidney, prostate, small intestine. According to several 
contemporary researchers, the increased activity of 
arginase II has been observed in much pathology 
such as diabetes, asthma, glomerulonephritis, 
psoriasis. As you know, arginase II inhibits еNOS, 
preventing the production of nitric oxide. A number 
of studies have established that inhibition of this 
enzyme increases the nitric oxide production and the 
prevention of dysfunctional disorders in the 
endothelium [12, 13, 14, 16, 17, 18, 19, 23]. 
Natural arginase inhibitors include amino acids 
such as ornithine, leucine, valine, lysine, isoleucine 
and norvaline. All inhibitors of arginase are divided 
into selective and non-selective, and specific acting 
directly on the enzyme and block its active site, and 
non-specific, acting on the enzyme indirectly. With 
the aim of inhibiting arginase there was used Nω-
hydroxy-l-arginine (NOHA), which is an 
intermediate in the synthesis of NO. However, due to 
the NOHA is a coenzyme of cytochrome P450, its 
administration was very difficult, and in return, he 
was synthesized Nω-hydroxy-nor-L-arginine (nor-
NOHA) [10, 24]. Also as an arginase inhibitor there 
was investigated £- difluoromethylornithine (DFMO) 
in vitro and in vivo. DFMO inhibits ornithine 
decarboxylase (ODC) and increases the amount of L-
arginine through the urea cycle. However, to reduce 
the activity of arginase large concentrations of 
DFMO are required, and it contributes to the 
independent vascular responses and accumulation of 
ornithine. Such substances as S-(2-boronoethyl)-L-
cysteine (BEC) and 2(S)-amino-6-boronohexanoic 
acid (ABH) swowed a high activity in reducing the 
activity of arginase. Another inhibitor of arginase is 
L-norvaline [1, 14, 15, 16, 24, 25].  
However, the described inhibitors of arginase 
are low-selective or non-selective and inhibit the 
activity of arginase II and arginase I. A decrease in 
the activity of arginase I associated with a number of 
side effects. In experiments with gene knockout of 
arginase I in mice there were observed symptoms of 
hyperammoniemia. All animals died within 10 to 14 
days of postnatal development [26]. 
That is why it is important to search for new 
highly selective inhibitors of arginase II, the study of 
their cardioprotective and endothelial protective 
effects. To date, the global pharmaceutical market 
has no drugs from the group of  arginase II selective 
inhibitors. That is why the aim of our study is 
increase the efficiency of pharmacological correction 
of ED using arginase II selective inhibitors, 
norleucine derivatives. 
RESEARCH OBJECTIVES 
1. To carry out the selection of potential
molecules arginase II selective inhibitors according 
to the criteria of selectivity and safety tests in vitro. 
2. In acute pharmacological experiments to
select antihypertensive doses of the most active and 
safe agent from the group of norleucine derivatives. 
3. To study endothelial protective and
cardioprotective effects of arginase II selective 
inhibitor under the code ZB49-0010C in dose 
flexibility on the L-NAME induced deficit of 
endogenous NO. 
4. To study endothelial protective and
cardioprotective effects of arginase II selective 
inhibitor under the code ZB49-0010C in dose 
flexibility on homocysteine-induced ED. 
5. To evaluate the antiischemic activity of the
arginase II selective inhibitor under the code ZB49-
0010C on the chronic limb ischemia on the 
background of L-NAME induced deficit of NO. 
MATHERIALS AND METHODS 
The experiments were performed in the 
laboratory of preclinical studies of the Center for 
preclinical and clinical studies of Belgorod State 
University in 520 male Wistar rats (weight 200±10 g, 
age 4-5 months) and 40 white mice of both sexes 
(weight 20±2 g; age 5-6 weeks). All experiments 
were approved by the Ethics Committee of Federal 
Autonomous Educational Institution of Higher 
Education Belgorod State University. Vivisection 
was carried out in accordance with the ethical 
principles for the treatment of laboratory animals of 
"The European Convention for the Protection of 
Vertebral Animals Used for Experimental and Other 
Scientific Purposes. CETS No. 123". The 
investigated substances were synthesized by High-
Technology Center “CHEMRAR”, under the 
leadership of the director general Dmitry 
Vladimirovich Kravchenko. Structures of the 
synthesized potential molecules are given in table 1. 
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Table 1 
Chemical structure of the investigated substances 
Laboratory 
code 
Full chemical name of agent Structure 
Molecular 
weight 
Z991-0104 1,2,4,7-tetraze- 5-tertbutylamino -6-[4H-
2,6- dimethoxyphenyl] pyrazine 
319 
ZB49-0009 
2-{1-[3-(thio isoxazole -5-yl) propyl] 
piperidine -4-yl}-6-( dihydroxyboryl) 
norleucine  
378 
ZB49-0010С 
2-{1-[3-(3-chloro isoxazole -5-yl) propyl] 
piperidine -4-yl }- 6-( dihydroxyboryl) 
norleucine dihydrochloride  
471.5 
Research methods in vitro. Study the specific 
activity of ZB49-0010С 
was carried out using the following biochemical 
reactions: 
Arginase II hydrolyses L-arginine to 
mercaptovalerate, which in the presence of a 5, 5'-
dithio-bis-(2-nitrobenzoic acid) (DTNB) is 
metabolized to the 5-thio-2-nitrobenzoic acid the 
characteristic yellow color. The activity of the 
arginase II is in direct ratio to the amount of 5-thio-2-
nitrobenzoic acid and measures 
spectrophotometrically by the intensity of yellow 
color at a wavelength of 405 nm. A known arginase 
II inhibitor ABH was used as a positive control and 
to determine a value of minimum signal of the 
experiment. IC50 (concentration of substance in µm 
which causes a 50% maximal effect) for ZB49-
0010С was determined from the graph of the 
concentration dependence of the inhibiting effect of 
the substance. The experimental data were analyzed 
in the GraphPad Prizm program (GraphPad Software, 
Inc., San Diego, CA). To graph concentration 
dependence there was chosen the equation: 
Y=Bottom curve + (Top curve-Bottom 
curve)/(1+10^((LogIC50-X)* Curve slope)). 
To verify the most promising molecules 
according to the criterion of safety it is necessary 
primary to study of the binding potential molecules 
arginase II selective inhibitors hERG channel of 
cardiomyocytes, as blocking of this channel leads to 
fatal consequences such as the disturbance of 
repolarization, QT interval increase and the 
subsequent development of asystole. 
Determination of the effect of the studied 
substances on the hERG channel was performed 
using in vitro test systems Invitrogen® PredictorTM 
hERG. There was investigated the binding substance 
the hERG channel in the composition of the 
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membrane fraction when the concentration of the 
drug 10 and 40 µmol. The method is based on 
changing the detection polarization of the 
fluorescence, which decreases as the displacement 
high-affinity fluorescent ligand tracer by the test 
substance. Experimental procedures were performed 
in accordance with the manufacturer's instructions to 
test the system PredictorTM hERG. 
Research methods in vivo. Experiments to 
study general toxical action in the acute toxicity of 
the arginase II selective inhibitor under the code 
ZB49-0010С were performed on white mice of both 
sexes weighing 22±2 g in accordance with the 
applicable guidelines on preclinical study of new 
pharmacological substances (Mironov A. N., 2012, 
R. U. Khabriev, 2005). 
Therapeutic dose calculation of ZB49-0010С. 
According to the study in vitro activity, ZB49-0010С 
at a concentration of 30 µmol has a 100% high 
selective inhibitory activity against the arginase II. 
On the basis of molecular weight 471.5, when the 
concentration of the solution equal to 30 µmol, dose 
of the agent in the volume of distribution of entire 
body is 14 mg/kg. As the circulating blood volume in 
rats is approximately 8-10% of body weight, the 
actual dose may be reduced to 10 times; therefore, a 
minimal therapeutic dose is 1 mg/kg. 
To study the hypotensive effect and the selection 
of effective doses there was performed acute 
pharmacological experiment. Thus arginase II 
selective inhibitor ZB49-0010С was administrated 
intragastric in doses of 1 mg/kg, 5 mg/kg and 10 
mg/kg. Measurement and record of the systolic blood 
pressure, diastolic blood pressure and heart rate were 
made for 30 min before the intragastric 
administration of ZB49-0010С, as well as after 15 
and 30 min, 1 and 2 hours after on the tail by a sensor 
and hardware-software complex MP 150 "Biopac-
systems" (USA), in animals without anesthesia in a 
holder at a temperature of 28
◦
 C, which was 
maintained with the help of a special heating 
chamber ("Biopac-systems", USA). 
1. To simulate ED male rats were administrated
intraperitoneal eNOS inhibitor L-NAME at a dose of 
25 mg/kg of body weight daily, 1 time per day for 7 
days. To simulate homocysteine-induced ED rats 
were administrated intragastric methionine 
(Polisintez, LLC, Belgorod) daily in a dose of 3 g/kg 
body weight, 1 time per day. On the 8th day from the 
start of the experiment under noninhalation 
anesthesia (chloral hydrate 150 mg/kg + zoletil 60 
mg/kg) the left carotid artery was catheterized for 
registration of hemodynamic parameters. Systolic 
blood pressure, diastolic blood pressure and heart rate 
were measured continuously by a sensor, the 
computer program AcqKnowledge 4.1 and hardware-
software complex MP 150 "Biopac-systems" (USA). 
There were performed functional tests for 
endothelium-dependent and endothelium-
independent vasodilatation with the following 
calculation of the CED [8, 27]. 
To study the contractile activity of the 
myocardium and hemodynamic parameters on the 
back of ED, in rats with anesthesia and automatic 
breathing there was performed catheterization of the 
left ventricle and there were measured continuously 
by a sensor, the computer program AcqKnowledge 
4.1 and hardware-software complex MP 150 
"Biopac-systems" (USA) hemodynamic parameters, 
such as left ventricular pressure, maximum 
contraction rate (+dp/dt max), maximum relaxation 
rate (-dp/dt max) and heart rate. There were 
performed functional stress tests in the following 
sequence: 
2. The test for adrenoreactivity
3. The overload resistance test (the clamping of
the ascending aorta for 30 sec) [8, 27]. 
4. Quantification of stable metabolites of NO.
As part of the study there was used a modification of 
the method for the quantification of stable 
metabolites of NO (Metelskaia V. A., 2005). 
Simulation the chronic limb ischemia of the hind 
limb in rats was performed with anesthesia (chloral 
hydrate 150 mg/kg and zoletil 60 mg/kg) by ligation 
with the intersection of the femoral artery beneath the 
inguinal ligament and removal of the portion of the 
great vessel, including the femoral, popliteal artery 
and primary departments of the crural arteries 
(Kolesnik, I. M., 2010). Assessment of the 
microcirculation level in the tibiotarsus muscles of 
the rats was performed with noninhalation anesthesia 
(chloral hydrate 150 mg/kg and zoletil 60 mg/kg) 
using a laser Doppler flowmeter "Biopac-systems" 
MP 150, needle sensor TSD-144 and program 
AcqKnowledge 4.1 [28, 29]. 
To confirm the development of simulated 
pathological processes and integrated assessment of the 
effectiveness of their correction in all series of 
experiment there was performed histomorphometric 
studies of the heart, kidneys and muscles of the hind 
limb.  
The results of the studies were statistically 
analysed. They calculated arithmetic means and 
standard errors. The significance of differences was 
Yakushev V.I., Pokrovskii M.V. Cardiovascular effects of an arginase II selective inhibitor. 
Research result: pharmacology and clinical pharmacology. Vol. 2, №3 (2016): 28-45. 
32 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
evaluated in Student t-test, Wilcoxon and Mann-
Whitney tests. IC50 was calculated by linear regression 
analysis. For the calculations there was used program 
for statistical analysis Microsoft Excel 2007. 
THE RESEARCH DESIGN 
To study dose-dependent pharmacological 
activity, ZB49-0010C was administered 
intragastrically at doses of 1 mg/kg, 5 mg/kg and 10 
mg/kg in acute pharmacological experiment and in 
the study of pharmacodynamic actionon in the long-
term experiment on the L-NAME induced and 
homocysteine-induced ED, as well as on the chronic 
limb ischemia. 
The study protocol of cardioprotective and 
endothelial protective effects of the arginase II 
selective inhibitor ZB49-0010C included the 
following sections: 
1. Simulation L-NAME induced and 
homocysteine-induced ED and its correction by the 
arginase II selective inhibitor ZB49-0010C for 7 days. 
2. Assessment of endothelium-dependent and
endothelium-independent reactions of arterial 
pressure on simultaneous intravenous introduction of 
acetylcholine and sodium nitroprusside with chloral 
hydrate anesthesia. 
3. Automatic breathing of animals, 
catheterization of the left ventricle, registration of the 
left ventricular pressure, +dp/dt, -dp/dt, heart rate. 
There were performed functional stress tests to assess 
functional reserves of the contractile activity of the 
myocardium. 
4. Blood sampling from the right ventricle for
biochemical analysis and euthanasia of animal. 
5. Sample collection of the heart and kidneys
for morphological studies. 
In the study of the antiischemic activity of the 
arginase II selective inhibitor ZB49-0010C there was 
developed the following research design: 
1. The group of intact animals
2. The sham-operated group of animals
3. The group with simulated limb ischemia
4. The group with simulated limb ischemia +
intraperitoneal administration of L-NAME at a dose 
of 12.5 mg/kg daily for 28 days. 
5. The group with simulated limb ischemia +
intraperitoneal administration of L-NAME at a dose 
of 12.5 mg/kg daily for 28 days + ZB49-0010С at a 
dose of 1 mg/kg 
6. The group with simulated limb ischemia +
intraperitoneal administration of L-NAME at a dose 
of 12.5 mg/kg daily for 28 days + ZB49-0010С at a 
dose of 5 mg/kg 
7. The group with simulated limb ischemia +
intraperitoneal administration of L-NAME at a dose 
of 12.5 mg/kg daily for 28 days + ZB49-0010С at a 
dose of 10 mg/kg 
8. The group with simulated limb ischemia +
intraperitoneal administration of L-NAME at a dose 
of 12.5 mg/kg daily for 28 days + L-norvaline at a 
dose of 1 mg/kg 
The study protocol of the antiischemic activity 
of the arginase II selective inhibitor under the code 
ZB49-0010C included the following sections: 
1. Mixed noninhalation anesthesia (chloral
hydrate intraperitoneally 150 mg/kg + zoletil 60 mg/kg) 
2. Dissection of skin and fascia
3. Measurement of microcirculation by LDF
4. Blood sampling from the right ventricle for
test concentration of stable metabolites of nitric oxide 
5. Sample collection of the muscles for
morphological study. 
RESEARCH RESULTS 
Study of specific activity and mechanism of 
action of bioactive molecule ZB49-0010С. The 
activity of the arginase II is directly proportional to 
the amount of 5-thio-2-nitrobenzoic acid and it was 
measured spectrophotometrically by the intensity of 
yellow color at a wavelength of 405 nm. A known 
inhibitor of the arginase II ABH was used as a 
positive control to determine value of minimum 
signal of the experiment. IC50  for ZB49-0010С was 
determined from the graph of the concentration 
dependence of the inhibitory effect of the substance 
(figure 1 and table 2).  Concentration dependence of 
the inhibitory effect of the substance ZB49-0010С 
and control substance ABH in relation to the arginase 
II is presented in figure 1. Each concentration point 
represents the average value for the two repetitions. 
Specific activity of ZB49-0010С in respect of the 
arginase II obtained in 2 independent experiments is 
shown in table 3. 
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Figure 1. Concentration dependence of the inhibitory effect of the substance ZB49-0010С 
and control substance ABH in relation to the arginase II 
Table 2 
Specific activity of ZB49-0010С in relation to the arginase II, obtained in two independent experiments 
Substance 
Max testing concentration 
(µmol) 
Substance activity in max 
concentration (%) 
IC50, (nmol) 
Numerical order of 
the experiment 
ZB49-0010С 30 99 22.0 1 
ZB49-0010С 30 100 19.7 2 
As can be seen from figure 1 and table 2, ZB49-
0010С has a nanomolar inhibitory activity against 
arginase II, as a complete inhibitor of the enzyme. 
The results of the binding potential molecules 
arginase II selective inhibitors hERG channel at 
concentrations of 10 and 40 µm in the composition of 
the membrane fractions using a test system 
Invitrogen
®
 PredictorTM hERG are presented in table 
3. 
Table 3 
The results of the binding potential molecules arginase II selective inhibitors hERG channel in the composition of the 
membrane fractions using a test system Invitrogen® PredictorTM hERG 
Substance 
hERG- dependence fluorescence polarization 
Concentration (µmol) 
Polarization, mP. Mean 
value (n=20) 
SD CV, % 
Non-bindind 
hERG, % 
Z991-0104 40 275 5.1 1.9 86 
ZB49-0009 40 245 5.0 2.1 87 
ZB49-0010 40 265 6.9 2.6 100 
Z991-0104 10 287 10.1 3.5 96 
ZB49-0009 10 271 5.4 2.0 97 
ZB49-0010С 10 268 3,0 1,0 100 
The data indicate the absence of the binding 
ZB49-0010С hERG channel at concentrations up to 40 
µmol (table 3). 
Conducted study of general toxical action in the 
acute toxicity showed that after a single intragastric 
administration to mice of the active pharmacological 
substance ZB49-0010C at the dose of 1438 mg/kg 
animal deaths were not observed within two weeks 
after administration of ZB49-0010C. According to the 
classification Sidorov, K. K., active pharmacological 
substance ZB49-0010C can be attributed to low-toxic 
substances. 
The results of the dynamic of the systolic blood 
pressure, diastolic blood pressure and heart rate in 
acute pharmacological experiment in animals without 
anesthesia treated ZB49-0010C are presented in 
figure 2. 
As shown by the results of acute pharmacological 
experiment (figure 2), ZB49-0010C has a dose-
dependent hypotensive effect, most pronounced at a 
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dose of 10 mg/kg, reaching its maximum after 30 min 
after a single intragastric administration, and not 
changing significantly up to 2 hours measurements of 
blood pressure. 
A B 
C 
Figure 2. The dynamic of dose-dependent effect of the ZB49-0010C on the systolic blood pressure (A), diastolic blood pressure 
(B) and heart rate (C) in rats without anesthesia in the acute pharmacological experiment. 
Comment: * – p<0.05 in comparison with group of intact animals 
Study of dose-dependent cardioprotective and 
endothelial protective effects of the arginase II 
selective inhibitor substances under the code ZB49-
0010C on the L-NAME induced deficit of 
endogenous NO. 
Dose-dependent effects of the ZB49-0010C at 
baseline blood pressure, CED, Total NO, 
adrenoreactivity, cardiac reserve and the diameter of 
cardiomyocytes in comparison with L-Norvaline in 
rats with anesthesia on the back of L-NAME-induced 
ED are presented in figure 3. 
Found that arginase II selective inhibitor 
substance under the code ZB49-0010C has a dose-
dependent endothelial protective effect, most 
pronounced at a dose of 10 mg/kg, which manifested 
in prevention of the increase in CED and approached 
of its values to the group of intact animals. Also there 
was found a dose-dependent antihypertensive action 
of ZB49-0010C, which is maximal at a dose of 10 
mg/kg on the back of L-NAME-induced deficit of 
endogenous NO. There was established a dose-
dependent cardioprotective effect of this 
pharmacological agent, which is most pronounced at 
a dose of 10 mg/kg and manifested in preventing the 
increase of the left ventricular pressure during the test 
for adrenoreactivity and the reduction of cardiac 
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reserve during the overload resistance test, and 
preventing the development of the left ventricular 
hypertrophy, identified by histological examination. 
The study of the dose-dependent 
cardioprotective and endothelial protective effects of 
the arginase II selective inhibitor substances under 
the code ZB49-0010C on the homocysteine-induced 
endothelial dysfunction. 
Dose-dependent effect of ZB49-0010C at 
baseline CED, Total NO, level of homocysteinemia, 
adrenoreactivity, cardiac reserve and the diameter of 
cardiomyocytes in comparison with L-Norvaline in 
rats with anesthesia on the back of homocysteine-
induced ED is presented in figure 4. 
Found that arginase II selective inhibitor 
substances under the code ZB49-0010C has a dose-
dependent endothelial protective effect, most 
pronounced at a dose of 10 mg/kg, which manifested 
in prevention of the increase in CED and approached 
of its values to the group of intact animals, and 
prevented the increase of the level of homocysteine 
in the blood plasma of rats and reduced the 
concentration of stable metabolites of nitric oxide. At 
the same time there was discovered a dose-dependent 
cardioprotective effect of this pharmacological agent, 
which is most pronounced at a dose of 10 mg/kg and 
manifested in preventing the increase of the left 
ventricular pressure during the test for 
adrenoreactivity and the reduction of cardiac reserve 
during the overload resistance test, and preventing 
the development of the left ventricular hypertrophy, 
identified by histological examination. 
A) Arterial pressure
B) Coefficient of endothelial dysfunction
Figure 3. Dose-dependent effects of the ZB49-0010C compared with L-Norvaline on baseline arterial pressure (A), 
CED (B), Total NO (C), adrenoreactivity (D), cardiac reserve (E), the diameter of cardiomyocytes (F)  
in rats with anesthesia on the back of L-NAME-induced ED 
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B) Total NO 
 
  
D) Adrenoreactivity 
                          
E) Cardiac reserve 
Figure 3 (continued). Dose-dependent effects of the ZB49-0010C compared with L-Norvaline on baseline arterial pressure 
(A), CED (B), Total NO (C), adrenoreactivity (D), cardiac reserve (E), the diameter of cardiomyocytes (F)  
in rats with anesthesia on the back of L-NAME-induced ED 
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F) Diameter of cardiomyocytes
Figure 3 (continued). Dose-dependent effects of the ZB49-0010C compared with L-Norvaline on baseline arterial pressure 
(A), CED (B), Total NO (C), adrenoreactivity (D), cardiac reserve (E), the diameter of cardiomyocytes (F) in rats with 
anesthesia on the back of L-NAME-induced ED 
Comment: * – p<0.05 in comparison with group of intact animals; ** – p<0.05 in comparison with the group 
 of animals with L-NAME-induced ED. 
A) Coefficient of endothelial dysfunction
B) Total NO
Figure 4. Dose-dependent effects of the ZB49-0010C compared with L-Norvaline on baseline CED (A), Total NO 
(B), level of homocysteine in the blood plasma (C), adrenoreactivity (D), cardiac reserve (E), the diameter  
of cardiomyocytes (F) in rats with anesthesia on the back of homocysteine-induced ED. 
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C) Level of homocysteine in the blood plasma 
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E) Cardiac reserve 
Figure 4 (continued). Dose-dependent effects of the ZB49-0010C compared with L-Norvaline on baseline CED (A), 
Total NO (B), level of homocysteine in the blood plasma (C), adrenoreactivity (D), cardiac reserve (E),  
the diameter of cardiomyocytes (F) in rats with anesthesia on the back of homocysteine-induced ED 
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F) Diameter of cardiomyocytes
Figure 4 (continued). Dose-dependent effects of the ZB49-0010C compared with L-Norvaline on baseline CED (A), 
Total NO (B), level of homocysteine in the blood plasma (C), adrenoreactivity (D), cardiac reserve (E), the diameter of 
cardiomyocytes (F) in rats with anesthesia on the back of homocysteine-induced ED 
Comment: * – p<0.05 in comparison with group of Tween; ** – p<0.05 in comparison with the group of animals with 
homocysteine-induced ED. 
The effects of the arginase II selective inhibitor, 
substances ZB49-0010C at the microcirculation level 
in the ischemic limbs on the back of L-NAME-
induced deficit of endogenous NO in experiment. 
The results of the evaluation of the 
microcirculation level in animals on day 29 in the 
ischemic limb on the back of L-NAME-induced deficit 
of endogenous NO and its correction by arginase II 
selective inhibitor, substances ZB49-0010C at doses of 
1, 5 and 10 mg/kg are presented in table 4. 
Table 4 
The results of the evaluation of the microcirculation level in the tibiotarsus muscles and the concentration 
of stable metabolites of NO (Total NO) in the blood plasma of rats on day 29. (M±m), PU (perfusion units)  
Group Perfusion units Total NО, umol/l 
Intact animals (n=20) 542.1 ±18.5 117.7 ±3.1 
Sham-operated animals (n=20) 540±3.7 120.3±4.0 
Animals with simulated limb ischemia (n=20) 360.8 ±8.7* 119.2 ±3.8* 
Simulated limb ischemia + L-NAME 12.5 mg/kg (n=20) 281.4±25.6** 61.3±4.2*** 
Simulated limb ischemia +L-NAME 12.5 mg/kg + 
ZB49-0010C 1 mg/kg (n=20) 
386.9 ±30.7*** 73.8 ±4.2*** 
Simulated limb ischemia +L-NAME 12.5 mg/kg + 
ZB49-0010C 5 mg/kg (n=20) 
583.6±36.7*** 91.6±6.4*** 
Simulated limb ischemia +L-NAME 12.5 mg/kg + 
ZB49-0010C 10 mg/kg (n=20) 
616.9±24.0*** 118.7±4.3*** 
Simulated limb ischemia +L-NAME 12.5 mg/kg + L-
norvaline 10 mg/kg (n=20) 
496.8±29.6*** 96.6±8.4*** 
Comment: * – p<0.05 in comparison with group of intact animals; ** – p<0.05 in comparison with the group of animals 
with simulated limb ischemia; *** – p<0.05 in comparison with the group of animals with simulated limb ischemia+L-NAME. 
As can be seen from table 4, the minimum 
microcirculation level in the tibiotarsus muscles was 
noted in the group of animals with simulated limb 
ischemia+ L-NAME. The influence of the arginase II 
selective inhibitor, substances ZB49-0010C at the 
microcirculation level was dose-dependent, 
maximum effect was observed at a dose of 10 mg/kg.  
Found that the arginase II selective inhibitor, 
substance ZB49-0010C has dose-dependent 
antiischaemic effect, which most pronounced at a 
dose of 10 mg/kg and consists of in preventing the 
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fall in microcirculatory level, and also a protective 
effect on histoarchitecture of the striated muscle 
tissue in the ischemic limb on the results of 
morphological studies (figure 5). It was found that 
one of the mechanisms of the antiischemic effect of 
ZB49-0010C is the activation of synthesis of 
endogenous NO due to increasing bioaccessibility of 
L-arginine. 
А B C 
D E F 
Figure 5. Photomicrography 200 х: Morphological examination of the tibiotarsus muscles of rats, 29 days of the experiment. 
A – group of intact animals; B – group with simulated limb ischemia; C – group with simulated limb ischemia 
+ L-NAME; D – group with simulated limb ischemia + L-NAME + ZB49-0010C 1 mg/kg; E – group with simulated limb ischemia 
+ L-NAME + ZB49-0010C 5 mg/kg; F – group with simulated limb ischemia + L-NAME + ZB49-0010C 10 mg/kg. 
Hematoxylin and eosin stain. 
Thus, in the study of the 3 most promising 
potential molecules, according to results of testing in 
vitro, a substance under laboratory code ZB49-
0010С from the group of norleucine derivatives 
shows most pronounced inhibitory activity (at a 
concentration of 30 µmol) against arginase II as its 
full inhibitor. This agent in vitro doesn’t bind 
hERG- channel and not inhibit it at concentrations 
up to 40 µmol, thus not affecting the membrane 
potential and the cardiac repolarization that 
indicates its potential safety. 
During a comprehensive in vivo studies, 
simulation L-NAME induced and homocysteine-
induced ED, as well as chronic limb ischemia on 
the back of deficit of endogenous NO, there was 
found that arginase II selective inhibitor substance 
under laboratory code ZB49-0010С from the group 
of norleucine derivatives has a dose-dependent 
antihypertensive action, endothelial protective, 
cardioprotective, antiischaemic effects, most 
pronounced at a dose of 10 mg/kg. 
EVALUATION 
According to current data, ED is the main risk 
prediction of the overwhelming majority of 
cardiovascular diseases, a key role in the 
pathogenesis of which, as already mentioned, is 
played the deficit of endogenous NO. As you 
know, L-arginine as the only substrate for NO 
synthesis is actively metabolized by arginase II. 
Increased activity of arginase II leads to a decrease 
in NO and, consequently, to the development of 
ED. According to several contemporary authors, 
the increased activity of arginase is observed in 
bronchial asthma, arthritis, glomerulonephritis, 
psoriasis, with the development of diabetic erectile 
dysfunction. Also there was confirmed the link to 
the high activity of arginase with the development 
of ED in rats. Inhibition of this enzyme increases 
the NO synthesis and prevents the dysfunctional 
disorders in the endothelium (figure 6) [4, 13, 14, 
15, 16, 17, 18, 19, 20, 2121]. Therefore, the most 
promising and expedient pathogenetically in the 
prevention and complex therapy of cardiovascular 
diseases is the use of highly selective arginase II 
inhibitors. As you know, today the world 
pharmaceutical market has no one drug from the 
group of arginase II selective inhibitors. There is a 
variety of different reasons, the main of which, in 
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our opinion, is the failure of the search of 
molecules possessing on the one hand, the high 
selectivity in respect of arginase II and 
pharmacological activity and, on the other hand, a 
wide therapeutic range and toxicological safety. 
That is why the search for active highly selective 
and safe potential molecules arginase II selective 
inhibitors requires not only a huge set of 
mathematical, physicochemical methodology, 
aimed at the synthesis and selection of the most 
innovative and promising agents, but its long term 
test both in vitro and in vivo in various models of 
disease. Therefore, we have consistently used 
complex methodological approaches as 
methodologies of selection of the most selective 
and safe substances in tests in vitro and with the 
use of validated models of pathology in vivo, 
which are directed to the study of the 
pharmacological activity of the most effective and 
safe molecule. 
In vitro tests established that the substance 
ZB49-0010С from the group of norleucine 
derivatives showed most pronounced inhibitory 
activity at a concentration of 30 mmol against 
arginase II, as its full inhibitor. This agent doesn’t 
bind hERG channel of cardiomyocytes and not 
inhibit it at concentrations up to 40 µmol that 
indicates its potential safety in respect of cardiac 
electrical stability. 
In our study, endothelial protective and 
cardioprotective effects of arginase II selective 
inhibitor ZB49-0010C were studied on L-NAME 
induced and homocysteine-induced ED. To 
simulate homocysteine-induced ED experimental 
animals were administered intragastrical the 
methionine at dose of 3 g/kg once a day for 7 days. 
A metabolite of methionine homocysteine, due to 
its high peroxide activity has a damaging effect on 
the endothelium. Free radicals react with 
synthesized in the endothelium NO and reduce its 
biological activity. Also homocysteine can 
intervene in synthesis of disulfides that, in addition 
to functional disorders of endothelial cells, 
stimulates proliferation of vascular smooth muscle 
cells, causing its remodeling. Endothelium-
independent vasodilatation in homocysteine-
induced ED is not as pronounced as in L-NAME-
induced deficit of NO. Perhaps this is due to 
reduced availability of exogenous NO and the 
smaller values of the initial arterial pressure. 
Apparently, this can explain the higher values of 
CED in L-NAME-induced ED. In the body, 
homocysteine promotes the synthesis and 
accumulation in the cell membranes and 
intercellular space of LDL and VLDLa and their 
oxidation and reduction the synthesis of sulfur 
containing glucosaminoglycans that leads to vessel 
wall laxity. Simulation of homocysteine-induced 
deficit of endogenous NO leads to increase of CED 
to 3.4±0.2 (0.9±0.1 in the group of intact animals), 
and at the same time to increase the concentration 
of homocysteine in the blood plasma up to 
51.0±2.0 µmol/l (8.3±4.3 µmol/l in the control 
group animals). Also simulation of homocysteine-
induced ED leads to a sharp decrease in the 
concentration of stable metabolites of NO (Total 
NO) in plasma of rats to the level of 68.9±4.3 
(19.0±4.3 in the group of intact animals). With the 
administration of methionine there was observed a 
sharp decline in the functional parameters of the 
myocardium after stress tests that shows the 
development of latent cardiac insufficiency. 
Simulation of ED has also been performed 
intraperitoneal injection of the eNOS inhibitor 
L-NAME to male rats at a dose of 25 mg/kg for 7 
days. L-NAME in the body is converted to the 
active inhibitor L-NNA, which inhibits NO 
synthesis by inhibiting the eNOS. Deficit of NO 
causes a reduction of endothelium-dependent 
vasodilators effects and increases the 
vasoconstrictor influences, disturbances of 
systemic and regional hemodynamic, increases 
blood pressure, leads to heart dysfunction, 
increases the expression of endothelial cell 
adhesion molecules and others.  
As a result of experiments, a seven-day 
blockade of NO-synthase with L-NAME led to the 
development of arterial hypertension (systolic 
blood pressure 191.2±6.4; diastolic blood pressure 
145.7±3.8 mm Hg, compared to the group of intact 
animals, systolic blood pressure138.2±3.6, 
diastolic blood pressure 103.9±2.7 mm Hg). In 
addition, develop of NO deficit manifested by the 
increase in CED fivefold in comparison with its 
values in the group of intact animals, the negative 
dynamics in the stress tests, the decrease in the 
concentration of stable metabolites of NO in the 
blood, myocardial hypertrophy and hypertrophy of 
VSMC. However, CED in animals with 
homocysteine-induced deficit of endogenous NO 
was lower than in animals with L-NAME – 
induced ED that makes you think about more 
severe violation of the ratio of endothelium-
dependent and endothelium-independent 
vasodilatation associated with administration of 
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L-NAME at a dose of 25 mg/kg than with the 
administration of methionine in dose 3 g/kg. 
The main objectives of our research were to 
study the specific activity of the substance most 
selective and safe molecule arginase II inhibitor 
ZB49-0010C from the group of norleucine 
derivatives on the ED and limb ischemia in 
experiment. Mechanism of action of arginase II 
selective inhibitor is due to its structural similarity 
with ornithine, which is one of the products of 
metabolism of the urea cycle. Indirect effects of 
the arginase II selective inhibitor to arginase 
activity are associated with inhibition of ornithine 
carbamyl transferase, which catalyzes the 
metabolism of ornithine citrulline in the urea cycle. 
The result is an excessive accumulation of 
ornithine, which inhibits arginase. Moreover, 
arginase selective inhibitor increases the 
endogenous synthesis of L-arginine from citrulline 
by inhibiting argininosuccinate synthetase. The 
suppression of the activity of argininosuccinate 
synthetase by the arginase II selective inhibitor 
leads to increase endogenous synthesis of 
L-arginine and restoration of NO synthesis [4, 10, 
14, 15, 16, 17, 18, 19, 24, 25]. In our study 
arginase II selective inhibitor ZB49-0010C were 
studied to identify its hypotensive action, 
endothelial protective and cardioprotective effects 
and anti-ischemic effect. Hypotensive effect of 
arginase II selective inhibitor ZB49-0010C was 
dose-dependent and most pronounced at a dose of 
10 mg/kg and was shown to prevent the increase in 
arterial pressure due to the blockade of eNOS. 
Endothelial protective effect of arginase II 
selective inhibitor ZB49-0010C was also dose-
dependent and most pronounced at a dose of 
10 mg/kg, which was manifested by decrease of 
CED to 2.3±0.3 in L-NAME – induced ED and to 
1.6±0.2 in homocysteine-induced ED. Endothelial 
protective effect of ZB49-0010C is due to the 
suppression of the activity of arginase II, thereby 
there is an increase the synthesis of the main 
vasodilator of endothelium NO. 
The results of the research have been 
identified cardioprotective effect of the arginase II 
selective inhibitor ZB49-0010C in both models of 
ED, which manifested positive dynamic in the 
stress tests (test for adrenoreactivity, overload 
resistance test). It was possible to identify the 
prevention of increase of adrenoreactivity and 
reduce cardiac reserve. Cardioprotective effect of 
the arginase II selective inhibitor ZB49-0010C, in 
our opinion, may be associated with increase 
endogenous synthesis of L-arginine by inhibiting 
activity of argininosuccinate synthetase and 
accumulation of L-arginine due to inhibition of 
arginase. In turn, L-arginine has several properties 
that are beneficial for the activity of the 
cardiovascular system, it facilitates membrane 
depolarization of endothelial cells and regulates 
the pH in these cells, as well as the pH of the 
blood, reduces blood viscosity, reduces the 
production of free radicals and removes them from 
the endothelial cells [3, 4, 5, 6, 7, 9, 14, 30]. 
A morphological study demonstrates 
prevention under the influence of arginase II 
selective inhibitor ZB49-0010C increase in 
transverse diameter of the cardiomyocytes in 
animals with L-NAME-induced and homocysteine-
induced ED. Also under the action of arginase II 
selective inhibitor ZB49-0010C has been observed 
a prevention of development of negative 
pathological processes in the kidneys which was 
most pronounced at a dose of 10 mg/kg. 
In the study of biochemical markers of ED in 
the blood plasma there was observed a prevention 
of the reduce of the concentration of stable 
metabolites of NO in L-NAME – induced 
pathology. In simulation of homocysteine-induced 
pathology there was also observed a prevention of 
the reduce of the concentration of stable 
metabolites of NO and an increase the level of 
homocysteine in the blood plasma which was most 
pronounced at a dose of 10 mg/kg. 
In the study of the anti-ischemic effect of 
arginase II selective inhibitor ZB49-0010C there 
was established prevention of falling of the 
microcirculation on the 29th day in the chronic 
limb ischemia which was the most significant at a 
dose of 10 mg/kg. A morphological study also 
revealed the most pronounced at a dose of 
10 mg/kg prevention the development of necrotic 
and atrophic processes in skeletal muscle of the 
ischemic limb and the protective effect on 
histoarchitecture of striated muscle. 
These effects are primarily associated with the 
increase of bioaccessibility of L-arginine as the 
main substrate for NO synthesis, due to the block 
of its biotransformation by arginase II. It leads to 
an increase of NO synthesis, which is an important 
factor that activates neoangiogenesis by increasing 
production of endothelial growth factor that 
stimulates the proliferation, migration of endothelial 
cells and activates local blood flow [5, 28, 29, 30]. 
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Figure 6. The pathogenesis of endothelial dysfunction and the application points of the action potential endothelial protective 
agents (L. Santhanam, D. W. Christianson, et al., 2008) 
The obtained data fully coincide with the results of 
other authors [13, 15, 17, 18, 21, 25, 31, 32, 33, 34, 35, 
36] and indicate the prospects for drugs suppressing the
activity of arginase II. The selectivity of the studied 
drug makes it more preferable because there is no 
impact on the urea exchange [4, 14, 16, 26]. 
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NOHA – Nω-hydroxy-l-arginine  
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